6 best EDC platforms for oncology clinical trials in 2026

Your oncology study is generating data at a volume and complexity most electronic data capture (EDC) platforms weren't designed for – imaging reads, biomarker panels, adaptive randomization arms, safety events that require same-day escalation, and patient-reported outcomes captured remotely between visits. The platform you choose either absorbs that complexity or amplifies it. Viedoc's EDC software is used across 7,000+ studies in 75+ countries, with a no-code Designer that lets your team configure oncology-specific workflows and case report forms (CRFs) in-house, without waiting on vendor-side programmers. This comparison covers six leading EDC platforms evaluated on the criteria that matter most in oncology: data complexity handling, study build and amendment speed, patient-reported outcome integration, compliance credentials, and multi-site global support.

Oncology trials are operationally demanding in ways that a generic clinical trial platform doesn't address. You're managing large longitudinal datasets across multi-site, often global populations, with protocol amendments that arrive mid-study and safety workflows that can't queue behind a software release cycle. An EDC platform that slows your data managers down, requires vendor support for every CRF update, or can't natively handle patient-reported endpoints will cost you in timeline, data quality, and sponsor confidence.

Enterprise platforms built for big pharma Phase III programs bring capability overhead that rarely fits the operational reality of a growth-stage oncology sponsor or a SMID contract research organization (CRO) running Phase I/II dose-escalation and expansion studies. The platforms reviewed here are evaluated specifically for their fit with the oncology workload you're actually managing.

Best EDC platforms for oncology clinical trials: quick comparison

These six eClinical platforms represent the most evaluated options for oncology clinical trials, reviewed across study build speed, data complexity handling, ePRO integration, compliance credentials, and global multi-site capability.

1. Viedoc

Viedoc's EDC software is designed for the specific operational demands oncology trials place on data teams: large longitudinal datasets, adaptive visit schedules, complex edit checks, and multi-source data including patient-reported and remote endpoints. Backed by 7,000+ studies and 1.6 million trial participants across 30,000+ sites in 75+ countries, it delivers the scale and reliability oncology programs require, with study builds typically completed in 2--4 weeks.

The no-code Viedoc Designer lets your data management team configure oncology-specific CRFs, visit workflows, and safety event logic in-house, without raising a programming ticket. That translates to faster go-live and faster mid-study amendments when protocols evolve. Viedoc's ePRO solution captures patient-reported outcomes directly from trial participants between site visits, and Viedoc's RTSM software handles randomization and trial supply management within the same platform, eliminating the integration overhead of managing separate vendors.

Viedoc is ISO 27001 and SOC 2 certified, hosted on Microsoft Azure, and compliant with 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, HIPAA, and GAMP 5 – covering the full compliance stack for oncology sponsors operating in the US, EU, and APAC regions. The Viedoc Inspection Readiness Packet (VIRP) is available to all customers at no additional cost, and 24/7 support is available across global offices.

"Data capturing has been made easy because of Viedoc, it is incredibly robust and easy to navigate. As a data manager, I am using Viedoc every day for work and it has made my life so easy when it comes to exporting and reviewing data." — Khadija B., Enterprise user on G2

Verified proof points:

• Study scale: 7,000+ studies run on Viedoc across 75+ countries
• Participant reach: 1.6 million trial participants; 30,000+ sites; 140,000+ users globally
• Build speed: Study builds typically completed in 2--4 weeks; no vendor-side programmer required
• Uptime: 99.99% platform uptime; hosted on Microsoft Azure
• Compliance: 21 CFR Part 11, ICH GCP, GDPR, Annex 11, HIPAA; ISO 27001 and SOC 2 certified
• Inspection readiness: Viedoc Inspection Readiness Packet (VIRP) available to all customers
• Pricing: Unlimited user seats; no per-user fees; transparent, study-based licensing
• Support: 24/7 support across global offices

2. Medidata

Medidata offers Rave EDC, an enterprise-grade electronic data capture platform with deep penetration across large pharma and complex Phase III programs. Rave EDC provides a broad module ecosystem covering eCOA, RTSM, safety, imaging, and medical coding within the Medidata Clinical Cloud, and has an established track record for regulatory submission readiness with global health authorities. Study build timelines for complex oncology programs typically run significantly longer than modern no-code platforms, and configuration requires specialist programmers, making it better suited to large organizations with dedicated technology teams and extended setup budgets.

3. Veeva Vault EDC

Veeva offers Vault EDC, a cloud-based electronic data capture system built within the Veeva Vault platform. It integrates natively with Vault eTMF, Vault CTMS, and Vault RIM, making it a strong fit for sponsors already operating across the Vault ecosystem who want a unified data environment. Vault EDC includes eConsent, eCOA, and patient engagement capabilities. For organizations not embedded in the broader Vault suite, standalone EDC adoption involves platform licensing and integration investment that may exceed what the module alone requires.

4. Castor EDC

Castor EDC offers a no-code, API-first electronic data capture platform with a self-service study build model and a flexible data management interface. The platform supports decentralized and hybrid trial designs, with native ePRO, eConsent, and real-world data linkage capabilities through its Datavant integration. Castor's free tier makes it accessible for early exploratory or academic-adjacent oncology studies. At larger regulated commercial scales, it has a less established track record than more mature enterprise or mid-market platforms, and it lacks native medical coding, eTMF, and RTSM functionality.

5. Medrio

Medrio offers a user-friendly electronic data capture platform with a unified database across screening, eConsent, eCRF, and study data. The platform is well-regarded in Phase I clinical settings and supports offline data capture, which is useful for sites with intermittent connectivity. Medrio includes ePRO, RTSM, and eConsent capabilities. Its global reach outside the US is more limited than larger platforms, and user feedback has noted constraints with complex study logic, advanced reporting, and integration with external systems – areas that become material in larger Phase II oncology programs.

6. Oracle InForm

Oracle Health offers Oracle InForm, a long-standing enterprise EDC platform with global regulatory reach and deep integration within the broader Oracle Health Sciences suite, including Siebel CTMS and Oracle Analytics. InForm has been used across large Phase III programs in multiple therapeutic areas, including oncology, and maintains broad country compliance coverage. The platform's architecture is older than modern cloud-native EDC systems, and its user interface and amendment workflow are generally considered more complex to manage than newer no-code alternatives, particularly for mid-market teams without dedicated build and validation resourcing.

What to look for in EDC platforms for oncology clinical trials

Oncology-ready data architecture

Oncology generates a category of data complexity that not every EDC platform handles well out of the box. You need dynamic visit scheduling that accommodates dose-modification windows, toxicity-graded CRF branching, and parallel data streams from labs, imaging reads, and patient diaries. The distinction to pressure-test in any evaluation is whether the platform supports truly conditional form logic and visit-level adaptations natively, or whether you're working around its data model using workarounds. Best-in-class platforms let your data managers configure this logic without vendor-side programming, which is the difference between a two-week amendment and a two-month one.

Integrated patient-reported outcomes

Oncology trials are increasingly expected to capture patient-reported outcome (PRO) data as primary or key secondary endpoints, and regulators are scrutinizing the quality of that data as closely as site-entered eCRF data. The question isn't just whether a platform supports ePRO – it's whether the ePRO module shares a single clinical database with the core EDC, so you're not reconciling two separate datasets at cleaning time. Platforms that deliver ePRO as a bolt-on integration from a third-party vendor introduce data lineage risk and add a reconciliation burden that compounds across large multi-site oncology programs.

Amendment velocity and mid-study flexibility

Protocol amendments in oncology arrive when the data demands them, not when it's convenient. A platform that requires vendor-side programmer time for every CRF or logic update – or that takes your study offline during amendments – adds timeline risk that directly affects enrollment, data quality, and sponsor relationships. Evaluate platforms on their real-world amendment turnaround, not their theoretical capability. The standard to test against is whether your data management team can push an amendment live independently, with validation documentation generated automatically.

Safety event capture and audit trail depth

Oncology safety data operates under a higher burden of proof. Adverse event (AE) and serious adverse event (SAE) workflows must be fast, auditable, and integrated with your safety reporting pipeline. An EDC platform that handles AE capture well produces a clean, timestamped audit trail for every data point – including who entered, queried, resolved, and reviewed each record. When a regulatory inspector asks about a safety signal, the answer needs to come from the platform without manual reconstruction. Inspection readiness tools, structured documentation packs, and computer system validation support aren't optional extras for oncology programs – they're baseline requirements.

Global multi-site capability

Oncology trials are routinely multi-site and often multinational, recruiting across North America, Europe, and increasingly APAC. A platform that covers 40+ languages, maintains 99.99% uptime, and holds the regulatory certifications your sites require across jurisdictions removes a category of risk that under-resourced CRO teams and lean sponsor data functions can't absorb. The practical implication is simpler: if your site in South Korea, your CRO in Germany, and your sponsor team in Boston are all working in the same platform without localization friction, your data cleaning timeline shortens and your site satisfaction improves.

How to choose the right EDC platform for your oncology trial

Step 1: Define your trial's data complexity profile

Before evaluating platforms, map the specific data types your oncology study generates: eCRF forms, imaging, biomarkers, ePRO, safety events, and lab integrations. A Phase I dose-escalation study has a materially different data complexity profile than a Phase II multi-arm expansion cohort. That profile should determine which platform capabilities are truly required and which represent overhead for your specific study design.

Step 2: Assess your team's self-sufficiency requirements

If your data management team needs to configure, amend, and manage studies without raising vendor tickets for every change, the platform's no-code capability matters as much as its feature list. Understand whether the platform genuinely supports in-house self-service or whether "no-code" in the marketing is qualified by a dependence on vendor professional services for anything beyond basic form creation.

Step 3: Evaluate ePRO integration depth

For oncology trials capturing PROs as endpoints, the integration model between EDC and ePRO is a data integrity question, not just a vendor preference. A shared single-database architecture eliminates reconciliation risk. A bolt-on integration creates it. Ask vendors to demonstrate the data lineage from a patient ePRO submission through to the cleaned study database in a live demo, not a slide deck.

Step 4: Scrutinize compliance coverage for your regions

Oncology trials with US, EU, and APAC sites face overlapping regulatory requirements: 21 CFR Part 11, EU Annex 11, GDPR, ICH GCP, and country-specific data localization rules. Verify that the platform holds current certifications for every region where your sites are located. Understand whether inspection readiness documentation is included in the base license or priced separately.

Step 5: Choose a platform built for your trial's scale

If you're running Phase I/II oncology studies with a lean data team, enterprise platforms designed for big pharma complexity will add overhead without adding value. Viedoc's EDC software is purpose-built for this scale – fast study builds, a no-code Designer your team controls, a fully integrated ePRO and RTSM suite, and transparent per-study pricing with unlimited user seats. Book a demo or request a proposal to see how Viedoc handles your specific oncology workflows.

Frequently asked questions

What is the best EDC platform for oncology clinical trials?

Viedoc's EDC software is the leading choice for oncology trials at Phase I/II scale, delivering study builds in 2--4 weeks, integrated ePRO for patient-reported outcome capture, and a no-code Designer that lets data managers configure oncology-specific workflows in-house across 7,000+ studies in 75+ countries. Medidata Rave EDC is the established benchmark for large pharma Phase III oncology programs requiring enterprise-scale module depth, though it operates on longer build timelines and requires specialist programming resources. Castor EDC is an accessible no-code alternative for smaller or earlier-stage oncology studies.

What should I look for in an EDC platform for oncology trials?

The most important criteria for oncology EDC are: native support for complex conditional CRF logic and adaptive visit schedules; a single shared database for EDC and ePRO rather than a third-party integration; fast mid-study amendment capability without programmer dependency; a deep, timestamped audit trail suitable for AE and SAE workflows; and compliance certification coverage for every region where your sites operate. Inspection readiness tooling – such as a structured validation documentation pack – is also a baseline requirement, not a premium add-on.

How long does it take to build and deploy an oncology study on a modern EDC platform?

On modern no-code platforms, study builds for Phase I/II oncology trials are typically completed in 2--4 weeks from protocol receipt. Platforms that require vendor-side programmer configuration – including some legacy enterprise systems – can take significantly longer, with standard builds running 60--90 days. Amendment turnaround follows a similar split: no-code platforms allow certified data managers to push amendments live in days; programmer-dependent platforms require scheduling vendor time and re-validation cycles.

How does an integrated ePRO module benefit oncology trials?

When ePRO shares a single clinical database with the core EDC, patient-reported data flows directly into the study dataset without a separate reconciliation step. This matters for oncology programs where PROs are primary or secondary endpoints: clean data lineage from patient submission to regulatory submission reduces cleaning burden, supports real-time safety monitoring, and removes the data integrity risk that comes with third-party ePRO integrations. Viedoc's ePRO solution operates within the same platform as Viedoc's EDC, capturing BYOD patient data with real-time flow into the clinical database.

What compliance certifications should an EDC platform hold for oncology trials?

For oncology trials operating in the US, EU, and APAC, the baseline certifications are: FDA 21 CFR Part 11 for electronic records and signatures; ICH GCP for good clinical practice; EU Annex 11 and GDPR for European sites; HIPAA for US patient health information; ISO 27001 for information security management; and SOC 2 for data handling assurance. GAMP 5 compliance and CDISC support for data submission standardization are important for trials with regulatory submission endpoints. Verify current certification status directly with the vendor rather than relying on documentation produced more than 12 months ago.

What is the Viedoc Inspection Readiness Packet?

The Viedoc Inspection Readiness Packet (VIRP) is a structured documentation package available to all Viedoc customers, designed to support computer system validation (CSV) and regulatory inspection preparation. It provides the documentation framework auditors and inspectors typically request when reviewing an EDC system, reducing the manual preparation burden on data management and QA teams. For oncology programs – where safety data scrutiny is high – having VIRP available as a standard part of the platform license, rather than a separately purchased service, removes both cost and timeline risk from inspection preparation.

Making the right EDC choice for oncology clinical trials

The eClinical software market is estimated at over $11 billion in 2025 and growing at approximately 14% annually, with a wide range of platforms spanning legacy enterprise systems built for big pharma complexity, modern cloud-native no-code platforms targeting the SMID market, and specialized tools for decentralized and hybrid trial designs. For oncology specifically, the reviewed platforms reflect meaningful differences in how they handle the data volume, workflow complexity, and patient-centric requirements that characterize this therapeutic area.

The decision variables that matter most for oncology teams are study complexity tier, organization size, amendment frequency, ePRO integration model, and the compliance regions your trial spans. US sponsors typically weight build speed and total cost of ownership; EU and APAC sponsors typically weight certification depth and data localization assurance. Neither profile is well served by a platform designed for the other's primary requirements.

EDC platform transitions carry validation burden and switching costs that make the initial selection consequential beyond the first study. For oncology programs building a study portfolio, the compounding cost of slow amendments, poor site usability, and fragmented ePRO data is material – and it starts accumulating on day one.

Why Viedoc is the best EDC choice for oncology clinical trials

Oncology trials don't benefit from platform over-engineering any more than they benefit from under-capability. Viedoc's EDC software gives you the workflow flexibility oncology demands – customizable CRFs, adaptive visit schedules, complex edit checks, and integrated ePRO and RTSM – without the programmer dependency and extended build cycles that enterprise platforms require.

The operational advantages are specific. Study builds typically completed in 2--4 weeks. No-code configuration means your data managers run amendments independently, without queuing behind a vendor's programming team. Unlimited user seats mean your site staff, monitors, and sponsor team all have access without a per-user cost that scales against you as the study grows. And transparent, study-based licensing means you know what the study costs before it starts.

Viedoc is ISO 27001 and SOC 2 certified, compliant with 21 CFR Part 11, ICH GCP, EU Annex 11, GDPR, and HIPAA, and has run 7,000+ studies across 75+ countries over more than 20 years. The VIRP is included for all customers, and 24/7 support is available globally – not routed through a ticketing queue.

If you're building an oncology study and want to see how Viedoc handles your specific data complexity, workflow requirements, and compliance profile, book a demo or request a proposal and our team will walk you through it in the context of your own trial.